← Back to Search

Monoclonal Antibodies

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cycle1 day1, cycle1 day15, cycle2 day1, cycle3 day1, cycle4 day1, cycle6 day1, cycle8 day1, cycle12 day1, cycle16 day1, end of treatment (maximum of 65.1 weeks of treatment)
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle1 day1, cycle1 day15, cycle2 day1, cycle3 day1, cycle4 day1, cycle6 day1, cycle8 day1, cycle12 day1, cycle16 day1, end of treatment (maximum of 65.1 weeks of treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle1 day1, cycle1 day15, cycle2 day1, cycle3 day1, cycle4 day1, cycle6 day1, cycle8 day1, cycle12 day1, cycle16 day1, end of treatment (maximum of 65.1 weeks of treatment) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Dose Limiting Toxicities (DLTs)
Secondary study objectives
Area Under the Concentration-time Profile From Time Zero to the Time Tau (AUCtau) of Elranatamab
Duration of Response (DOR)
Minimal Residual Disease (MRD) Negativity Rate
+11 more

Side effects data

From 2023 Phase 1 trial • 4 Patients • NCT04798586
100%
Cytokine release syndrome
75%
Pneumonia
75%
Neutropenia
50%
Weight decreased
50%
Lymphopenia
50%
Hypogammaglobulinaemia
50%
Diarrhoea
50%
Fall
50%
Injection site reaction
50%
Pyrexia
25%
Nasopharyngitis
25%
Death
25%
Malaise
25%
Sepsis
25%
Vertigo
25%
Cytomegalovirus infection
25%
Anaemia
25%
Hypoalbuminaemia
25%
Dysgeusia
25%
Arthralgia
25%
Leukopenia
25%
Conjunctivitis
25%
Oral candidiasis
25%
Skin abrasion
25%
Otitis media
25%
Hypophosphataemia
25%
Neuropathy peripheral
25%
Cytomegalovirus infection reactivation
25%
Headache
25%
Oropharyngeal pain
25%
Rash
25%
Insomnia
25%
Tooth loss
25%
Bronchitis
25%
Hypokalaemia
25%
Wound
100%
80%
60%
40%
20%
0%
Study treatment Arm
Elranatamab

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Elranatamab (PF-06863135)Experimental Treatment1 Intervention
BCMA-CD3 bispecific antibody
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Elranatamab (PF-06863135)
2021
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,673 Previous Clinical Trials
17,827,119 Total Patients Enrolled
41 Trials studying Multiple Myeloma
10,731 Patients Enrolled for Multiple Myeloma
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,554 Previous Clinical Trials
14,867,930 Total Patients Enrolled
29 Trials studying Multiple Myeloma
5,936 Patients Enrolled for Multiple Myeloma
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top